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Synaptotagmin 1 (SYT1) is a critical mediator of fast, synchronous, calcium-dependent neurotransmitter release and also modu-
lates synaptic vesicle endocytosis. This paper describes 11 patients with de novo heterozygous missense mutations in SYT1.
All mutations alter highly conserved residues, and cluster in two regions of the SYT1 C2B domain at positions Met303
(M303K), Asp304 (D304G), Asp366 (D366E), Ile368 (I368T) and Asn371 (N371K). Phenotypic features include infantile hypo-
tonia, congenital ophthalmic abnormalities, childhood-onset hyperkinetic movement disorders, motor stereotypies, and develop-
mental delay varying in severity from moderate to profound. Behavioural characteristics include sleep disturbance and episodic
agitation. Absence of epileptic seizures and normal orbitofrontal head circumference are important negative features. Structural
MRI is unremarkable but EEG disturbance is universal, characterized by intermittent low frequency high amplitude oscillations.
The functional impact of these five de novo SYT1 mutations has been assessed by expressing rat SYT1 protein containing the
equivalent human variants in wild-type mouse primary hippocampal cultures. All mutant forms of SYT1 were expressed at levels
approximately equal to endogenous wild-type protein, and correctly localized to nerve terminals at rest, except for SYT1M303K,
which was expressed at a lower level and failed to localize at nerve terminals. Following stimulation, SYT1I368T and SYT1N371K
relocalized to nerve terminals at least as efficiently as wild-type SYT1. However, SYT1D304G and SYT1D366E failed to relocalize to
nerve terminals following stimulation, indicative of impairments in endocytic retrieval and trafficking of SYT1. In addition, the
presence of SYT1 variants at nerve terminals induced a slowing of exocytic rate following sustained action potential stimulation.
The extent of disturbance to synaptic vesicle kinetics is mirrored by the severity of the affected individuals’ phenotypes, suggesting
that the efficiency of SYT1-mediated neurotransmitter release is critical to cognitive development. In summary, de novo dominant
SYT1 missense mutations are associated with a recognizable neurodevelopmental syndrome, and further cases can now be diag-
nosed based on clinical features, electrophysiological signature and mutation characteristics. Variation in phenotype severity may
reflect mutation-specific impact on the diverse physiological functions of SYT1.
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Introduction
Healthy brain function relies on tight regulation of the prob-
ability and timing of neurotransmitter release (Waites and
Garner, 2011; Jahn and Fasshauer, 2012). A fundamental
step in this pathway is the calcium-dependent triggering of
fusion between synaptic vesicle and plasma membranes to
enable coordinated fast neurotransmitter release. The synap-
totagmins are a family of integral synaptic vesicle proteins
required for the synchronous coupling of activity-dependent
calcium influx to synaptic vesicle fusion at central synapses.
Synaptotagmin 1 (SYT1) is the primary cerebral isoform, ex-
pressed throughout the neocortex and subcortical structures
in postnatal life (http://www.braineac.org/). SYT1 triggers
synaptic vesicle fusion by binding calcium via highly con-
served cytoplasmic C2A and C2B domains, followed by
penetration of the plasma membrane bilayer by a series of
hydrophobic residues within these domains (Sudhof, 2013).
In addition, SYT1 plays a modulatory role in endocytosis
(Poskanzer et al., 2003; Yao et al., 2011), and has recently
been implicated in the calcium-sensitive trafficking of postsy-
naptic AMPA receptors to facilitate long term potentiation
(Wu et al., 2017). SYT1 therefore influences multiple aspects
of synaptic physiology necessary for neurotransmission and
synaptic plasticity.
We previously described the first case of a human disorder
associated with a rare variant in SYT1 (Baker et al., 2015).
The individual harbouring a de novo mutation (I368T)
presented with an early onset mixed hyperkinetic movement
disorder, severe motor delay, and profound cognitive impair-
ment. Structural MRI was normal, but EEG showed exten-
sive neurophysiological disturbances. Expression of rat SYT1
containing the equivalent human mutation in wild-type
mouse primary hippocampal cultures altered the kinetics of
exocytosis and endocytosis, in agreement with the role
for I368 in calcium-dependent membrane penetration
(Paddock et al., 2011). A second de novo missense variant
in SYT1 (M303K) was identified within a series of patients
with dysmorphology and developmental delay (Cafiero
et al., 2015). Neurological symptoms were not reported
for this second case, motor milestones were less severely
delayed, and cognitive impairment was also less severe. As
in the first case, EEG abnormalities were reported despite no
overt seizures.
Defining the syndrome associated with mutations in SYT1
requires validation by the identification of further individuals
with similar mutation characteristics and phenotypic features.
To this end, we now report medical, neurological and devel-
opmental phenotypes for the two previously reported patients
and nine new patients with de novo SYT1 mutations. This
case series provides sufficient evidence that rare missense mu-
tations in SYT1 are associated with a distinctive neurodeve-
lopmental phenotype and EEG abnormality. The presence of
recurrent mutations clustered around the calcium-binding
pocket of the C2B domain suggests potential mechanisms of
disease. Functional assessment of the five mutations further
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supports pathogenicity, and points toward genotype-specific
synaptic pathophysiology.
Materials and methods
Patient identification and consent
Identification of patients with de novo SYT1 mutations began
after reporting the first case (Baker et al., 2015). The cohort
reported here emerged from direct contact from clinicians and
genomics research groups with similar cases recognized from
reporting the first case. Patients were selected by clinicians in
10 different centres for diagnostic investigation via exome
sequencing or genome sequencing, on either a clinical or re-
search basis, in view of unexplained neurodevelopmental
disorders.
Consent for genetic testing was obtained via approved pro-
cedures at each local contributing centre. After genetic diagno-
sis, written consent to collate and report clinical data was
obtained from parents or guardians under Cambridge Central
Research Ethics Committee approval (IRAS 83633, REC ref:
11/0330/EE), plus specific additional consent for publication
of patients’ photographs or videos.
Sequencing methods
The methodology of variant identification for Patient 1 has been
previously published, using trio analysis of a customized whole
exome bait (Agilent Technologies) designed for the UK10K
Project (Baker et al., 2015). Variants for Patients 2 and
5 were identified via trio exome analysis using Agilent
Sureselect Exome V4, with average read depth coverage of
50–100 . Patients 3, 4 and 10 were identified by GeneDx se-
quence provider (Gaithersburg, USA) using trio analysis with
Agilent Clinical Research Exome as bait, with mean exome
coverage of 165 , 84 and 106 , respectively. The method-
ology for Patient 6 was previously reported, using a SureSelect
Mbp All exon kit 2.0 (Agilent Technologies) (Cafiero et al.,
2015). Patient 7’s variant was identified via trio exome analysis
using Agilent Sureselect Exome V5. Patient 8’s variant was
identified via trio exome analysis using Illumina exome capture
(38Mb target) at the Broad Institute, Cambridge USA. Patient
9’s variant was identified by trio exome sequencing at the
Human Genome Sequencing Center at Baylor College of
Medicine using the Nimblegen SeqCap EZ HGSC VCRome
Kit. Patient 11’s variant was identified by whole genome se-
quence analysis at HudsonAlpha Institute of Biotechnology,
using non-amplified genomic DNA in the Illumina HiSeq X
Ten sequencing system, with 150 bp paired-end reads with a
minimum coverage of 20 per base for 80% of bases.
In all cases the de novo SYT1 variant was identified using
standard variant calling and rare variant annotation methods.
All de novo SYT1 variants were confirmed by either Sanger
sequencing or repeat exome analysis using an independent
pull-down method (Patient 8). In all cases this was the only
likely pathogenic rare de novo variant reported. There were no
likely pathogenic X-linked variants in male patients.
Molecular modelling and molecular
dynamics simulations
To investigate the potential impact of mutations on the struc-
ture of the SYT1 C2B domain, 41 ms molecular dynamics
simulations were performed on C2B models derived from a
Ca2+ -bound solution nuclear magnetic resonance (NMR)
structure (PDB 1k5w; note that amino acid numbering used
follows human sequence for simplicity) generated using
Molsoft ICM Pro (for full details see Supplementary material).
The root-mean-square deviations (RMSD) of the backbone
atoms of each SYT1 C2B domain variant, compared to the
starting structures, were plotted over the complete trajectories
of the simulations (Supplementary Fig. 1A). This measures the
average variations in distances between the backbone atoms of
each protein over time, providing a readout of the change in
protein structure over time. The Ca2+ -binding ability of the
C2B domains was analysed by tracking the distances between
the bound Ca2+ ions and the gamma carbon of Asp363
(equivalent to human Asp364) throughout the trajectories
(Supplementary Fig. 1B and C).
Clinical phenotyping
Historic and contemporary neurological and neurodevelopmen-
tal records were reviewed for all patients. A list of Human
Phenotype Ontology terms found to be associated with SYT1
mutation is provided in Supplementary Table 1 (Kohler et al.,
2017). Where possible, video recordings of patients were sup-
plied for neurological review. All EEG recordings and reports
were reviewed by a paediatric neurophysiologist.
Functional studies
Site-directed mutagenesis was used to introduce the human mu-
tations into the homologous position in rat SYT1 (human/rat:
M303/3024K, D304/3034G, D366/3654E, N371/3704K,
amino acid numbering used henceforth follows human sequence),
which was fused to a pH-sensitive EGFP (pHluorin) at its lume-
nal N-terminus. Mutagenesis was performed using QuikChange
II Site-directed Mutagenesis kit (Agilent Technologies); mutagenic
primers are listed in Supplementary Table 2, and mutations were
confirmed by sequencing. SYT1I368T–pHluorin was made as pre-
viously described (Baker et al., 2015).
Dissociated primary hippocampal-enriched neuronal cultures
were prepared from embryonic Day 16.5–18.5 C57BL/6 J
mouse embryos as described (Baker et al., 2015; for full details
see Supplementary material). Cells were transfected after 7–8
days in culture and were used for fixation or live cell imaging
assays after 13–16 days in culture.
For SYT1 expression and localization assays, neurons were
first washed with saline buffer and then either fixed immedi-
ately (basal), exposed to 50mM KCl buffer for 30 s and then
fixed immediately (KCl depolarization), or exposed to 50mM
KCl buffer for 30 s and then allowed to recover in saline buffer
for 2.5min before being fixed (recover) (all performed at
37C) and immunolabelled (further details are available in
the Supplementary material).
Live fluorescence imaging assays were performed using SYT1-
pHluorin. Cultures were stimulated with a train of 1200 action
potentials at 10Hz in saline buffer or high Ca2+ buffer (4mM
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CaCl2 in place of 2mM CaCl2), supplemented with the V-type
ATPase inhibitor 1mM bafilomycin A1. Further information re-
garding acquisition conditions and analysis are detailed in the
Supplementary material.
All statistical analyses were performed using Microsoft Excel
and GraphPad Prism software. One-way, two-way or repeated
measures ANOVA with Dunnett’s multiple comparison test
was used for data comparing mutants to wild-type protein,
or with Tukey’s multiple comparison test to compare changes
in SYT1 localization and for experiments performed at differ-
ent Ca2+ concentrations. P50.05 was considered significant.
Data availability
The primary genetic data that support the findings of this
study are openly available for Patient 1 in the European
Genome-phenome Archive (https://www.ebi.ac.uk/ega/home)
within study accession number EGAS00001000128, dataset
accession EGAD00001000416. Data for Patients 8, 9 and 11
are available in dbGaP (https://www.ncbi.nlm.nih.gov/gap)
within project numbers phs001272, phs000711.v5.p1 and
phs001089, respectively. Data for the remaining participants
are held within clinical diagnostic services and are not publicly
available. All reported SYT1 variants have been deposited in
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).
Results
SYT1 variant evaluation
Seven different rare de novo non-synonymous variants were
identified in 11 patients (Table 1), resulting in five different
amino acid substitutions (M303K n = 1, D304G n = 1,
D366E n = 3, I368T n = 4, N371K n = 2). All variants
are absent from GnomAD database (version 2.0, accessed
3 September 2017) (http://gnomad.broadinstitute.org) (Lek
et al., 2016). At position 371 a common synonymous vari-
ant is documented, but no non-synonymous changes have
been observed to date amongst healthy controls. A single
loss of function variant at position 303 is reported. The
protein overall is constrained for missense and loss of func-
tion variation (http://exac.broadinstitute.org/). Mutations are
clustered in one of two regions of the protein (Fig. 1A). All
mutations occur at residues highly conserved throughout
evolution and in addition are located within highly con-
served blocks of amino acids within the protein (Fig. 1B).
Figure 1C shows positions of the mutated amino acids
within a 3D structure of the SYT1 C2B domain. All five of
the mutations map to the Ca2+ ion binding region of the
C2B domain. Met303 packs into the interior of the domain
against Ile374 and the aliphatic portion of Lys301. Two
mutations, Asp304Gly and Asp366Glu occur in residues
that directly contact both bound Ca2+ ions. Ile368 plays
a critical role in the Ca2+ -dependent penetration of SYT1
into the lipid membrane, and is thus central to the func-
tional role of the protein (Paddock et al., 2011). A hydro-
philic residue at this position (Ile368Thr) is incompatible
with insertion into the hydrophobic interior of the plasma
membrane. Asn371 helps to define both the conformation
of one of the Ca2+ binding loops and the position of the
Ca2+ residue forming a ligand at Asp366.
To examine whether patient-identified mutations affect
SYT1 structure, we performed molecular modelling and mo-
lecular dynamics simulations of the C2B domain. The average
RMSD of each mutant model, which measures the divergence
of the mutant protein structure from its initial structure over
the course of the simulation, revealed that structural transi-
tions occurred in the C2B domain incorporating M303K,
which did not occur in the wild-type protein (Fig. 1D and
Supplementary Fig. 1A). While most mutations did not affect
the Ca2+-binding ability of the C2B domain, the average
percentage of time bound for both Ca2+ ions across the simu-
lation was significantly lower for D304G compared to wild-
type (Fig. 1E, P = 0.0028 Ca2+ 1, P = 0.0001 Ca2+ 2;
D304G versus wild-type, two-way ANOVA with Dunnett’s
multiple comparison test). Therefore, these simulations pro-
vide evidence that SYT1 mutations may alter the structure of
the C2B domain and could thus be expected to have deleteri-
ous impact on SYT1 function.
Case histories
For case history details see Table 1.
General health
Family histories, pregnancies and birth histories were unre-
markable. No patient required neonatal resuscitation or
intensive care. Congenital anomalies were absent, with ex-
ception of bilateral talipes in one individual and atrial
septal defect (spontaneous closure) in another. Physical
health during infancy and childhood was generally good.
Feeding difficulties were reported for three children (diffi-
culty chewing and swallowing solids), and gastro-oesopha-
geal reflux was diagnosed in four. Central sleep apnoea was
a feature in three patients, requiring supplemental oxygen
during infancy but resolving by early childhood. Medical
complications have been observed for the two individuals
currently over the age of 10 years. Patient 1 (I368T) pre-
sented at age 11 years with paroxysmal episodes of cyan-
osis with an altered respiratory pattern, diagnosed on sleep
study as hyperventilation-triggered apnoeas due to hypo-
carbia. Subsequent treatment with iron, clonidine and inter-
mittent oxygen led to significant improvement of these
episodes. Patient 3 (D304G) developed severe gastro-oe-
sophageal reflux during his teenage years associated with
food refusal, and also progressive lower limb contractures
and scoliosis (surgically managed with poor outcome of
reduced mobility).
Physical examination
Physical examination did not identify any consistent con-
genital abnormalities. Growth parameters indicated linear
growth within the normal range. Notably, orbitofrontal
circumferences were in the normal range (5th to 75th per-
centiles) and maintained during childhood. Comparison
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Figure 1 SYT1 de novo mutations cluster in the C2B domain. (A) 2D cartoon of SYT1 domain structure depicting position of patients’
mutations (Jay and Brouwer, 2016). (B) Evolutionary conservation at mutation sites. (C) Structure of the C2B domain of SYT1 in ribbon
representation coloured grey (McNicholas et al., 2011). Mutated residues are shown in ball and stick representation coloured in atom colour
(carbons orange) and Ca2 + ions in cyan. The side chains of Ile374 and Lys301, which pack against Met303, are shown in grey ball and stick
representation. (D and E) Simulations (1.3 ms) were performed on C2B models derived from the calcium-bound soluble NMR structure
(PDB 1k5w). Models of the mutant C2B domains were generated using Molsoft ICM Pro. (D) The average RMSD of the backbone atoms of
each protein, compared to the starting structures, across all frames in the simulations. Data are mean  standard error of the mean (SEM).
(E) The Ca2 + -binding ability of the C2B domains was analysed by tracking the distances between the bound calcium ions and the gamma carbon
of Asp363 (equivalent to human Asp364) throughout the trajectories. Data are percentage occupancies  SEM at the calcium 1 (filled) and
calcium 2 (striped) sites for each protein over the simulation time; calcium ions were considered bound if the distances between the ions and the
gamma carbon of Asp363 were 56 A˚. *P5 0.01, **P5 0.0001 versus wild-type, two-way ANOVA with Dunnett’s multiple comparisons tests.
SYT1 case series BRAIN 2018: 141; 2576–2591 | 2581
between photographs and clinical genetics evaluations sug-
gested facial similarities between individuals, namely a
prominent high forehead with V-shaped hairline, horizontal
low-set eyebrows, mild epicanthus, almond-shaped eyes,
fine facial features with short nose and prominent nasal
tip, smooth philtrum and thin upper lip (Supplementary
Fig. 2).
Neurological symptoms
The earliest sign of potential neurological impairment was
infantile hypotonia, which was universal within the cohort.
Patients were described as under-reactive to stimulation
during the first year of life. Another common early feature
was ophthalmic abnormality (strabismus in six cases, nys-
tagmus in five cases) with poor visual attention and central
visual impairment reported as a frequent later feature.
Post-infantile dystonic and hyperkinetic involuntary
movement abnormalities currently affect four patients,
with mutations I368T (two of four cases) and N371K
(two of two cases). Symptom severity ranges from dystonic
posturing and mild chorea to severe mixed movement dis-
order with vocal dystonia and ballismus. Illustrative videos
are provided in the Supplementary material. A third case of
I368T (Patient 10, currently age 3 years) demonstrates re-
petitive leg movements, stereotypies (hand clapping, throw-
ing body backward) and possible lower limb dystonia,
suggestive of evolving movement disorder with similarity
to older patients with the same mutation. Three patients
with mutation D366E, one patient with mutation D304G
and one patient with I368T are not reported to have invol-
untary movements, but do manifest stereotypies such as
repetitive leg kicking, finger chewing, object mouthing
and head or chest tapping. One individual (M303K) is re-
ported to have ataxia and impaired fine motor abilities, but
no other movement abnormalities. No individual within the
cohort has been diagnosed with a seizure disorder.
Neurodevelopment
Motor delay is reported to be mild in one individual
(M303K), but is severe in the remainder (age of sitting
independently 13 months to 4 years, one individual not
yet sitting independently at age 4 years; age of walking
independently 2–10 years, seven individuals not yet walk-
ing independently at ages 3–21 years). Speech and language
skills are severely to profoundly impaired in 10 of 11 pa-
tients, with nine individuals using no words. However,
Patient 6 (M303K) is reported to use around 50 words at
the age of 7 years, indicating a milder degree of intellectual
disability.
For all patients, behavioural disturbance is a major con-
tributor to impairment and familial distress. Parents report
a characteristic alternating pattern of switching between
calm and excited or agitated phases, without apparent ex-
ternal triggers. During agitated phases, which can last be-
tween minutes and days, common problems include
increased involuntary movements, screaming episodes,
chest-beating, mouthing objects, chewing on fingers or
hands, and minor self-injury. Impaired social development
is also a common feature. Six of eleven individuals are re-
ported to show no eye contact or poor eye contact, with
limited interest in social interactions and absence of normal
imitative behaviours. However, others are described as gen-
erally happy and socially engaged, except during episodes
of agitation. Sleep disturbance is a major feature in at least
seven patients, with frequent night waking and difficulty
returning to sleep persisting to late childhood.
Treatment histories
A wide range of anti-epileptic treatments have been trialled
(in view of EEG abnormality and severe neurodevelopmen-
tal impairment) including carbamazepine, sodium valpro-
ate, lamotrigine, leviteracetam, ethosuximide and
ketogenic diet. Beneficial effects of these interventions
have not been reported by clinicians or families, and sed-
ation has been a frequent side-effect.
The two oldest patients have both been prescribed cloni-
dine, and this was found to be beneficial in reducing sleep
disorder and hyperventilation-induced cyanotic episodes.
We report our experience with treating Patient 1 (I368T)
with pramipexole, a dopamine agonist with affinity for D2,
D3 and D4 receptors, which is an established treatment
option for parkinsonian movement disorders in adults
and children. In view of functional evidence that the
patient’s mutation alters the kinetics of neurotransmitter
release, we hypothesized that a drug that amplifies post-
synaptic function could potentially enhance synchronous
neurotransmission. SYT1 is the major synaptotagmin iso-
form in the basal ganglia, where it plays an essential role in
regulating calcium-dependent axonal dopamine release
(Mendez et al., 2011). Thus it was theorized that circum-
venting the impact of reduced dopaminergic release in the
basal ganglia might potentially have a beneficial effect on
striatal function and involuntary movements. Patient 1 has
been treated daily with pramipexole for 3 years, with
clinician-observed and parent-reported reduction in severity
of movement disorder, reduced frequency and severity of
agitated and self-injurious behaviours, and increased re-
sponsiveness to social and environmental stimuli. EEG
abnormalities have also lessened. Based on a single patient
open-label treatment experience we cannot conclude
whether these improvements reflect a true response to
medication or a coincident progression of the natural his-
tory of the patient’s disorder.
Neuroimaging and electrophysiology
All patients underwent cranial MRI on at least one occa-
sion during diagnostic evaluations. Brain structure and
qualitative assessment of maturation were reported as
normal in seven cases. Delayed maturation was noted in
one case. For Patient 7 (N371K), MRI at 6 months was
reported to be normal but at 25 months of age periven-
tricular white matter changes of uncertain significance were
noted (Supplementary Fig. 3). For Patient 8 (D366E), MRI
brain in infancy identified a choroid plexus haemorrhage,
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and a repeat MRI brain at 3 years of age was normal. For
Patient 11 (I368T), MRI at 1 year showed mild generalized
prominence of extra-axial CSF and patchy increased T2
signal in periventricular white matter of uncertain signifi-
cance. No striatal or thalamic pathology or volume loss
was reported for any case. Magnetic resonance spectros-
copy was carried out for two cases and was normal in
both.
All patients had clinical EEG recorded on at least one
occasion during diagnostic evaluations, with abnormalities
noted in all (Fig. 2). In all but one case, normal variable
features of background activity were absent, and recordings
were dominated by symmetrical bursts of high amplitude
low frequency synchronous activity. The frequency of this
slow wave activity varied with age (51 year: frequency 1–
3/s; 2–4 years: frequency 2.5–4/s; 58 years: frequency 5–6/
s). Despite the absence of overt seizures, additional epilepti-
form abnormalities were reported in five individuals. These
features include multifocal spikes, isolated spike bursts, iso-
lated sharp waves and generalized spike wave discharges,
most often with parietal-occipital maxima. For patients
with multiple recordings available at different ages during
childhood, epileptiform features decline with age, and some
age-appropriate rhythms are observable by late childhood.
Patient 9 (D366E) had a single EEG recording at 12
months of age, at which point background activity was
Figure 2 SYT1 de novo mutations are associated with low frequency oscillation bursts on EEG. Clinical EEG acquired for 6 of 11
patients with SYT1 mutations during early childhood. EEG for three patients with recurrent mutation SYT1 I368T: (A) Patient 2, age 8 months.
(B) Patient 1, age 2 years. (C) Patient 10, age 3 years. EEG for patients with other mutations: (D) Patient 4, mutation SYT1 D366E, age 2 years.
(E) Patient 5, mutation SYT1 N371K, age 2 years. (F) Patient 7, SYT1 N371K, age 3 years. Scale: x = 1 s, y = 600 mV.
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reported to be normal, with the presence of rare low amp-
litude spikes from the right occipital region during
drowsiness.
Effect of SYT1 mutations on the
expression and trafficking of SYT1
protein
We first assessed whether mutations in SYT1 affected the
ability of the protein to be expressed or targeted to central
nerve terminals. Cultured hippocampal neurons were trans-
fected with SYT1 variants and then immunolabelled for
both EGFP (to identify transfected neurons) and SYT1
(Fig. 3A). This allows the level of expression of SYT1 vari-
ants to be determined by comparing to non-transfected cells
in the same field of view.
Most SYT1 variants were expressed to equivalent levels as
wild-type SYT1 (SYT1WT), with total SYT1 levels approxi-
mately double (1.7–1.9-fold) that of non-transfected cells
(Fig. 3B). However, M303K displayed a significantly lower
expression level than SYT1WT (Fig. 3B, P = 0.0088 com-
pared to SYT1WT, one-way ANOVA with Dunnett’s mul-
tiple comparison test). Thus, all SYT1 variants, except
SYT1M303K, were expressed in neurons at an approximately
equal proportion to that of endogenous SYT1, effectively
mimicking the heterozygous nature of the clinical cases.
We next determined how efficiently SYT1 variants were
targeted to nerve terminals. Coefficient of variation (CV)
analysis was used to measure the localization of SYT1,
where a high CV equates to a punctate distribution of
fluorescence intensity, indicative of efficient localization to
synaptic vesicles at nerve terminals, while a low CV equates
to a diffuse distribution of fluorescence, indicative of the
protein being more widely distributed throughout the axon
(Lyles et al., 2006; Gordon and Cousin, 2013). All SYT1
variants, with the exception of SYT1M303K, targeted effi-
ciently to nerve terminals at rest (Fig. 4B). SYT1M303K dis-
played a more diffuse localization than SYT1WT, and had a
significantly lower CV (Fig. 4C, P = 0.0064 compared to
basal SYT1WT, two-way ANOVA with Dunnett’s multiple
comparison test). Therefore, SYT1M303K is dysfunctional in
its level of expression and retention at nerve terminals.
We next determined whether there were any global defects
in the ability of SYT1 variants to be mobilized upon neur-
onal activity. During depolarization-induced Ca2+ influx,
synaptic vesicles undergo exocytosis and SYT1 escapes the
nerve terminal and is redistributed towards the periactive
zone. SYT1 is subsequently retrieved from the plasma mem-
brane by synaptic vesicle endocytosis (Fig. 4A). The activity-
dependent change in the fluorescence profile of neurons
expressing each SYT1 variant was therefore monitored
before, during or after depolarization with 50mM KCl.
We first examined the effect of the identified mutations on
the activity-dependent redistribution of SYT1 fluorescence
out of nerve terminals during synaptic vesicle exocytosis
(Fig. 4B). This was achieved by monitoring the decrease in
CV on stimulation. As expected, CV immediately after
stimulation was significantly lower than CV at rest for
SYT1WT, indicating that evoked synaptic vesicle exocytosis
had occurred. This was also the case for all SYT1 variants
(Fig. 4C, basal versus KCl, wild-type P = 0.0098; D304G
P = 0.0012; D366E P = 0.0001; I368T P = 0.0002; N371K
P = 0.0001; two-way ANOVA with Tukey’s multiple com-
parison test), with the exception of SYT1M303K, which was
already mislocalized before stimulation.
Next, we assessed whether these mutations affected the re-
enrichment of SYT1 at nerve terminals, which is reliant on
efficient synaptic vesicle endocytosis. Neurons were
Figure 3 SYT1 mutants, except M303K, are expressed as
efficiently as wild-type protein. Cultured hippocampal neurons
were transfected with SYT1 variants. (A) Representative images of
neurons transfected with SYT1 variants (tagged with pHluorin, a
variant of GFP), fixed at rest and immunolabelled for GFP and SYT1.
Greyscale panels (left) highlight transfected neurons (GFP), and false
colour panels (right) display SYT1 immunofluorescence staining,
with warmer colours indicating more intense staining. Arrowheads
highlight transfected (filled) and non-transfected (open) nerve ter-
minals. Scale bar = 5mm. (B) Bar graph shows SYT1 immunofluor-
escence intensity in transfected neurons relative to non-transfected
neurons in the same field of view. Data displayed as mean  SEM,
n = 3–4. **P5 0.01 compared to wild-type, one-way ANOVA with
Dunnett’s multiple comparison test.
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depolarized with 50mM KCl and allowed to recover in
standard saline buffer for 2.5min, and the fluorescence pro-
file of each SYT1 variant was again measured. This recovery
period is sufficient for endocytosis to take place and for the
reclustering of synaptic vesicles, and thus re-enrichment of
SYT1WT, at nerve terminals (Fig. 4B and C, KCl versus re-
cover, wild-type P = 0.0011; two-way ANOVA with Tukey’s
multiple comparison test). SYT1I368T and SYT1N371K were
also re-enriched at nerve terminals during the recovery
period (Fig. 4B and C, KCl versus recover, I368T
P = 0.0234; N371K P = 0.0024; two-way ANOVA with
Tukey’s multiple comparison test), displaying a similar local-
ization profile to SYT1WT. In contrast, both SYT1D304G and
SYT1D366E remained diffusely localized after stimulation, and
the CV of these variants remained significantly lower than
that at rest (Fig. 4B and C, basal versus recover, D304G
P = 0.0146; D366E P = 0.0028; two-way ANOVA with
Tukey’s multiple comparison test) and thus these variants
Figure 4 SYT1 variants display mutation-specific defects in trafficking. Cultured hippocampal neurons transfected with SYT1 variants
were fixed at rest (basal; B), or immediately after 30 s incubation with 50 mM KCl (KCl; K), or after 2.5 min recovery in standard saline buffer
following 30 s depolarization with 50 mM KCl (recover; R). All steps were performed at 37C. (A) Diagram showing the localization of synaptic
vesicle proteins (dark blue) in a presynaptic terminal at rest (left, basal), following stimulation (middle, KCl), and after recovery (right, recover).
Colour intensity of background in presynaptic terminal represents fluorescence intensity of labelled proteins. Arrows (pink) indicate direction of
change in protein localization and fluorescence signal. (B) Representative images of neurons transfected with SYT1-pHluorin variants, fixed and
immunolabelled for GFP. Scale bar = 5 mm. (C) The distribution of fluorescence intensity along neurites determined by CV analysis, where a high
CV equates to a punctate localization, indicative of targeting to presynaptic terminals. Data is mean CV  SEM, n = 5–9. #P5 0.05, ##P5 0.01
compared to wild-type within same condition, two-way ANOVA with Dunnett’s multiple comparison test. *P5 0.05, **P5 0.01, ***P5 0.001
compared to basal; +P5 0.05, + +P5 0.01 compared to KCl; all by two-way ANOVA with Tukey’s multiple comparison test.
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did not efficiently relocalize to nerve terminals. This suggests
that the retrieval of SYT1D304G and SYT1D366E from the
plasma membrane was arrested, resultant from either a gen-
eralized defect in endocytosis, or a specific failure of these
variants to be recognized by the endocytic machinery.
Effect of SYT1 mutations on the rate of exocytosis
The protein localization assay revealed that synaptic vesicle
exocytosis proceeds in the presence SYT1 mutants; how-
ever, it provides no information regarding the kinetics of
exocytosis. To examine this in real time, we used the gen-
etically-encoded reporter SYT1-pHluorin (a pH-sensitive
form of EGFP, fused to the lumenal domain of SYT1),
which was expressed in cultured hippocampal neurons.
pHluorin fluorescence is quenched inside the acidic lumen
of synaptic vesicles but fluorescence increases upon expos-
ure to the neutral extracellular medium during exocytosis.
Fluorescence is quenched again following endocytosis as
nascent synaptic vesicles are re-acidified. Exocytosis can
be investigated specifically by arresting synaptic vesicle
acidification with the V-type ATPase inhibitor bafilomycin
A1. This permits a quantification of both the rate and
extent of synaptic vesicle fusion during neuronal activity.
Neurons transfected with SYT1-pHluorin variants were sti-
mulated with a train of 1200 action potentials at 10Hz in the
presence of 1mM bafilomycin A1, and both the extent and rate
of the evoked fluorescence increase was monitored. When the
aspartate SYT1 variants SYT1D304G and SYT1D366E were
examined, evoked exocytosis was able to proceed, as evidenced
by the increase in pHluorin fluorescence upon stimulation (Fig.
5A). The proportion of total synaptic vesicles that underwent
fusion (i.e. the recycling pool of vesicles) was also unaffected
by these SYT1 variants (Fig. 5C). However, the presence of
SYT1D304G and SYT1D366E resulted in a slowing of exocytosis
compared to SYT1WT (Fig. 5A, P5 0.05 SYT1D304G and
SYT1D366E versus SYT1WT, repeated measures ANOVA with
Dunnett’s multiple comparison test). The severe effect of
SYT1D304G was reflected by a reduction in the initial rate of
exocytosis over the first 20 s of stimulation (Fig. 5B,
P = 0.0042 SYT1D304G versus SYT1WT, one-way ANOVA
with Dunnett’s multiple comparison test). In contrast,
SYT1D366E had a milder effect (Fig. 5A) and did not signifi-
cantly reduce the initial rate of exocytosis (Fig. 5B, P = 0.1365
SYT1D366E versus SYT1WT one-way ANOVA with Dunnett’s
multiple comparison test).
We next investigated the remaining non-aspartate SYT1
variants. Similarly to SYT1D304G, the recycling pool of ves-
icles was not affected by SYT1I368T or SYT1N371K (Fig. 5F),
but exocytic rate was reduced in comparison to SYT1WT
(Fig. 5D, P5 0.05 SYT1I368T and SYT1N371K versus
SYT1WT, repeated measures ANOVA with Dunnett’s mul-
tiple comparison test; Fig. 5E, P = 0.0388 SYT1I368T and
P = 0.0362 SYT1N371K versus SYT1WT, one-way ANOVA
with Dunnett’s multiple comparison test). Mislocalization
of SYT1M303K precluded it from examination with this
assay.
Since increased Ca2+ influx can mitigate the clinical symp-
toms of similar mutations in the related gene SYT2 (Herrmann
et al., 2014; Whittaker et al., 2015), these exocytosis assays
were repeated in the presence of increased extracellular Ca2+
(4mM, in place of normal physiological 2mM Ca2+), to de-
termine if this could ameliorate SYT1 mutant-dependent slow-
ing of exocytosis. At 4mM Ca2+, exocytosis remained slower
for SYT1 variants in vitro compared to SYT1WT (Fig. 5G and
H, P50.05 SYT1D304G, SYT1D366E, SYT1I368T and
SYT1N371K versus SYT1WT 4mM, repeated measures ANOVA
with Tukey’s multiple comparison test). Importantly, however,
the exocytic rate with all SYT1 variants at 4mM Ca2+ was
restored to that of SYT1WT at 2mM Ca2+ (Fig. 5G and H,
P4 0.05 SYT1D304G, SYT1D366E, SYT1I368T and SYT1N371K
versus SYT1WT 2mM, repeated measures ANOVA with
Tukey’s multiple comparison test). Therefore, increasing extra-
cellular Ca2+ in vitro can normalize the rate of synaptic vesicle
exocytosis back to physiological levels in neurons expressing
SYT1 variants.
Discussion
We report here the clinical characteristics of 11 patients
with de novo missense mutations in SYT1. Mutations in
this gene are associated with a recognizable neurodevelop-
mental phenotype comprising infantile hypotonia, ophthal-
mic abnormalities with delayed visual maturation, sleep
disturbance, movement abnormalities, motor delay and in-
tellectual disability. We have been struck by the similarity
in behavioural features across this case series. Parents
report an alternating, unpredictable pattern of activity,
switching between calm and excited states without obvious
provocation. These behavioural characteristics are inde-
pendent of the severity of intellectual disability or presence
of movement disorder, hence may be useful diagnostic
markers.
Movement abnormalities are an important aspect of the
condition, and a spectrum of severity has been observed
within the case group. Dystonia, dyskinesia or hyperkinetic
movement disorder has been diagnosed in four patients.
Hence the presence of an involuntary movement disorder
may be suggestive of SYT1 mutation, but absence does not
preclude this diagnosis. In other cases, review of parental
video material has revealed less severe movement abnorm-
alities, for example repetitive leg kicking and posturing, not
reaching threshold for neurological classification. Motor
stereotypies are common within the group: hand-biting
and finger-chewing is a prominent stereotypy for the ma-
jority of individuals, whilst head-butting and chest-beating
are also observed in some cases. Distinguishing these repeti-
tive actions from true involuntary movements is not
straightforward, requiring multiple observations in different
settings and at different times of the day. Longitudinal data
on this relatively young cohort will establish whether invol-
untary movement disorder emerges in a higher proportion
of patients with time, and will clarify whether there is a
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Figure 5 SYT1 mutants slow evoked exocytosis. Hippocampal neurons transfected with SYT1-pHluorin variants were stimulated with a
train of 1200 action potentials at 10 Hz, in the presence of 1 mM bafilomycin A1 to block vesicle reacidification. (A and D) Time course of mean
F/F0 of SYT1-pHluorin variants normalized to stimulation peak. (B and E) Mean initial rate of exocytosis calculated from linear fit of F/F0 per
second over the first 20 s of stimulation (normalized to stimulation peak). (C and F) Total vesicle pool mobilized by 1200 action potentials at
10 Hz, normalized to NH4Cl peak. (A)
†P5 0.05 for SYT1D304G-pH and *P5 0.05 for SYT1D366E-pH against SYT1WT-pH over time indicated
by bar [wild-type (WT) n = 6, D304G n = 7, D366E n = 6, repeated measures ANOVA with Dunnett’s multiple comparisons test]. (B) **P5 0.01
(n as in A, one-way ANOVA versus wild-type with Dunnett’s multiple comparisons test). (C) Not significant by one-way ANOVA, n as in A.
(D) *P5 0.05 for SYT1I368T-pH and †P5 0.05 for SYT1N371K-pH against SYT1WT-pH over time indicated by bar (wild-type n = 7, I368T n = 5,
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(continued)
predictable sequence of symptom evolution and resolution.
Age is unlikely to be the only predictor of symptom severity
since the age range of patients currently manifesting an
involuntary movement disorder (3–14 years) is similar to
the age range of currently unaffected patients (3–21 years).
Beyond prognostication, diagnosis of SYT1-associated
neurodevelopmental disorder can have important treatment
implications. No beneficial effect of anti-epileptic drug
(AED) treatment has been observed on either neurodeve-
lopmental outcome or electrophysiological abnormalities.
In contrast, patients revealed side effects mainly consisting
of sedation. Hence AED treatment for patients harbouring
SYT1 mutations should be considered with caution. We are
encouraged by the potential benefits of the dopamine agon-
ist pramipexole. Initiation of pramipexole in Patient 1 was
associated with rapid and sustained reduction in involun-
tary movements and agitation; however, this treatment has
yet to be trialled in a second patient.
We have collated clinical EEG data for all patients and
found that electrophysiological abnormality is a consistent
hallmark of SYT1 mutation. Recordings are dominated by
bursts of synchronous, slow wave, high voltage activity
plus isolated epileptiform spike activity. The presence of
typical EEG features will provide important supportive evi-
dence for pathogenicity in future diagnostic evaluations.
However, there is also electrophysiological variation be-
tween cases. Oscillatory bursts vary in durations, cycle fre-
quency and cerebral distribution, and the extent and
morphology of spike activity is also variable. Potential ex-
planations for this variation include differences between
patients in EEG recording conditions, for example medica-
tion status, use of melatonin during recordings, and arousal
status. Age at clinical EEG recordings may also be an im-
portant factor, since we observe an increase in oscillatory
frequency and reduction in spike activity with age. Another
possible source of variation could be genotype-specific elec-
trophysiological signatures. Although we surmise that all
SYT1 mutations disturb subcortical-cortical network prop-
erties, leading to unconstrained low frequency synchronous
activity, the severity and clinical consequence of this dis-
turbance may vary. These differences may arise from the
specific impact of each mutation on synaptic physiology,
for example whether the amino acid substitution disturbs
calcium binding or membrane penetration, which will be
characterized in future studies, and consequent influence of
these mutations on synaptic vesicle dynamics and network
activity.
The presence of recurrent de novo missense mutation
associated with a specific disease is most commonly ex-
plained by specific dominant negative or gain-of-function
effects, such as those in FGFR3 causing achondroplasia
(Bellus et al., 1995). On the other hand, the presence of
non-recurrent missense mutations can lead to a variety of
loss- and gain-of-function effects, associated with pheno-
typic variability, as has been observed for SCN8A and
GABRG2 (Blanchard et al., 2015; Warner et al., 2016).
To obtain further evidence for the pathogenicity of
newly-identified mutations and explore physiological cor-
relates of patients’ phenotypes, we introduced rat SYT1
mutants (equivalent to the five patient-identified mutations)
into primary hippocampal cultures to screen for global de-
fects in SYT1 functionality. SYT1M303K is unique in that it
was expressed at lower levels than SYT1WT, with reduced
targeting to nerve terminals at rest as well as reduced som-
atic expression (Supplementary Fig. 4). Molecular model-
ling predicts that, of the mutations examined, M303K
produces the greatest change to the structure of the C2B
domain, potentially compromising the expression, stability
or trafficking of this variant. This may limit deleterious
dominant-negative effects or constitute loss of function in
neurons, resulting in the individual harbouring this SYT1
variant displaying the mildest neurodevelopmental impair-
ment within the cohort.
Further examination of mutants that displayed normal
expression and localization profiles at rest, revealed that
these were able to be mobilized upon depolarization, indi-
cating that exocytosis was not abolished (indeed, cessation
of exocytosis would be incompatible with life).
Interestingly, SYT1 variants with mutations of Ca2+ -bind-
ing residues were not retrieved following depolarization as
efficiently as the wild-type protein, indicating that these
residues might be important for either the specific traffick-
ing of SYT1 back to vesicles or for facilitating synaptic
vesicle endocytosis globally. Future studies will be required
to tease apart these distinct pathways. This suggests that
endocytic defects contribute to the pathophysiology of
neurological dysfunction in individuals harbouring these
mutations. Previous studies using multi-site C2A/C2B
domain aspartate mutants [D230 232N in C2A in combin-
ation with D363, D365N in C2B (D365 in rat is equivalent
Figure 5 Continued
N371K n = 6, repeated measures ANOVA with Dunnett’s multiple comparisons test). (E) *P5 0.05 (n as in D, one-way ANOVA versus wild-type
with Dunnett’s multiple comparison test). (F) Not significant by one-way ANOVA, n as in D. (G and H) Hippocampal neurons transfected with
SYT1-pHluorin variants were perfused with high (4 mM) Ca2 + buffer (wild-type 4 mM, D304G, D366E, I368T, N371K) or normal Ca2 + buffer
(wild-type 2 mM), and were stimulated with a train of 1200 action potentials at 10 Hz, in the presence of 1 mM bafilomycin A1 to block synaptic
vesicle re-acidification. (G) Time course of mean F/F0 of SYT1-pHluorin variants normalized to stimulation peak. P5 0.05 for SYT1
D304G
#P5 0.05 for SYT1I368T-pH, *P5 0.05 for SYT1D366E-pH, and †P5 0.05 for SYT1N371K-pH, against 4 mM SYT1WT-pH over time indicated by bar
(n = 8 for 4 mM wild-type, D366E, I368T; n = 7 for 2 mM wild-type, D304G, N371K, repeated measures ANOVA with Tukey’s multiple com-
parisons test). (H) Same data as in G, but cut-off at 40 s for clarity. All data represented as mean  SEM.
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to D366 in human)] revealed the importance of these Ca2+ -
binding residues for efficient endocytosis. Expression of this
multi-site mutant in SYT1 knockout mouse neurons failed
to rescue the kinetics of endocytosis back to wild-type
levels (Yao et al., 2011). However, mutation of D363,
D365N in the C2B domain alone had no effect on the
retrieval of SYT1 to synaptic vesicles following stimulation
(Yao et al., 2011). This may be a result of the nature of the
mutations (D366/5E versus D365N), or the different sti-
muli used in these studies evoking different modes of endo-
cytosis. Alternatively, endogenous wild-type SYT1 may be
preferentially retrieved over aspartate mutant SYT1 in our
culture system, while the D363, D365N SYT1 mutant was
examined in neurons lacking endogenous SYT1. It will be
important to ascertain in future work whether there is a
stimulation threshold or stimulation intensity dependence
for deficient retrieval of SYT1 C2B aspartate mutants.
SYT1 has well-defined functions in mediating evoked
synchronous neurotransmitter release, both through its
membrane-penetrating ability and interactions with fuso-
genic exocytic machinery (Martens et al., 2007; Hui
et al., 2009; Zhou et al., 2015, 2017). These functions
are heavily dependent on the C2B domain (Mackler
et al., 2002; Nishiki and Augustine, 2004; Paddock et al.,
2011). All neurodevelopmental disease-associated variants
of SYT1 that were correctly targeted to nerve terminals
were observed to slow the rate of exocytosis, noting that
our experimental paradigm does not allow distinction be-
tween synchronous and asynchronous release. The down-
stream neurophysiological impact of slowed exocytosis on
postsynaptic activation, neural network activity and infor-
mation processing is likely to be cell-type specific i.e.
impact maximally in regions and neuronal subpopulations
where other SYT isoforms are unavailable to compensate.
Accordingly, SYT1 is the major isoform mediating terminal
dopamine release in the midbrain, providing a potential
explanation for involuntary movement disorders (Mendez
et al., 2011). Moreover, SYT1 expression in the neocortex
increases during prenatal and early postnatal brain devel-
opment, then plateaus and declines from mid-childhood
(Kang et al., 2011) (hbatlas.org), in line with our observa-
tions of the natural history of patients’ symptoms and elec-
trophysiological phenotype.
We found preliminary evidence for genotype–phenotype
correlation, both with regard to clinical presentation and
impact on exocytosis in vitro. D366E has the mildest effect
on exocytic rate; correspondingly, individuals harbouring the
D366E variant manifest milder motor delay, devoid of early-
onset movement disorder, but retaining characteristic EEG
abnormalities and severe cognitive impairment. The milder
effect of this mutant recapitulates work in Drosophila,
where an equivalent syt variant was largely able to rescue
synchronous release (Nishiki and Augustine, 2004). In con-
trast, mutations to the residue equivalent to D304 were only
able to partially rescue neurotransmitter release (Nishiki and
Augustine, 2004). Correspondingly, we observe a severe cog-
nitive outcome and severe impairment in exocytic rate in
association with the D304G variant. Both patients with
N371K and two of four patients with I368T presented
with early-onset dystonia and choreo-athetosis plus severe
to profound intellectual disability. Both variants were
observed to have a similarly severe impact on exocytic
rate. Mutation at I368 has previously been shown to have
a dominant-negative effect on neurotransmitter release by
impeding membrane penetration (Paddock et al., 2011).
This is the first study to investigate mutation of N371,
hence further investigation is required to define a molecular
mechanism of action. Identification of additional patients
and mutations, plus experimentally controlled data on elec-
trophysiological characteristics and symptom correlates, are
required to confirm and extend these observations.
Clinical symptoms in individuals harbouring mutations in
the related gene, SYT2, can be improved by 3,4-diamino-
pyridine, a K+ channel blocker that increases Ca2+ influx
into the nerve terminal during neuronal activity (Whittaker
et al., 2015). We hypothesized that increasing extracellular
Ca2+ levels could ameliorate exocytic defects induced by
SYT1 mutants. Importantly, we found that this intervention
in vitro could nullify the effect of these variants, such that
exocytosis proceeded at the wild-type rate at physiological
Ca2+ concentrations. Further studies are required to inves-
tigate the impact of exocytic rate and its manipulation on
neural circuit activity in vitro and in vivo model organisms,
to inform potential therapeutic strategies for individuals
with SYT1-assosciated neurodevelopmental disorder.
Several other genes involved in neurotransmitter release
have been implicated in neurodevelopmental disorders.
Mutations in PRRT2, which influences Ca2+ -dependent
synchronous release via interaction with SYT1 (Valtorta
et al., 2016), lead to benign infantile familial seizures, par-
oxysmal movement disorders and intellectual disability
(Ebrahimi-Fakhari et al., 2015). Mutations in the plasma
membrane SNARE protein SNAP-25 result in epilepsy and
intellectual disability (Hamdan et al., 2017); these muta-
tions occur in or near residues that bind directly to the
C2B domain of SYT1 (Zhou et al., 2017). Mutations in
proteins that regulate endocytosis, such as synaptophysin
and dynamin 1, have also been linked to neurodevelopmen-
tal disorders involving movement abnormalities and EEG
disturbance (Ferguson et al., 2007; Tarpey et al., 2009;
Gordon et al., 2011; Kwon and Chapman, 2011; von
Spiczak et al., 2017). Intriguingly, a dominant-negative mu-
tation in UNC13A, which accelerates synaptic vesicle
fusion, is also associated with dyskinesia and intellectual
disability, reinforcing the importance of tight regulation
of the kinetics of neurotransmission (Lipstein et al.,
2017). Diagnosis of further patients with mutations in
these genes, systematic characterization of phenotypes,
and identification of additional disorders of synaptic vesicle
cycling will determine the extent of convergence between
presynaptic pathway-associated disorders.
In summary, we report the identified mutations and clin-
ical phenotypes for 11 individuals with SYT1 mutation,
and assessment of the impact of these mutations on SYT1
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functionality. Collectively, these data confirm that SYT1
mutation is associated with a recurrent neurodevelopmental
disorder. We found that each of these mutations detrimen-
tally affect either the expression and localization, or func-
tionality of SYT1. Variation in clinical phenotype severity,
in combination with differential effects of SYT1 mutants
in vitro, points toward mutation-specific mechanisms
underlying neurological dysfunction. Characterization of
this new disorder highlights the key roles of SYT1 in pre-
synaptic vesicle dynamics and the developmental emergence
of motor control and cognitive abilities.
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